Inhibitor of apoptosis (IAP) proteins are overexpressed in multiple human malignancies, an event that is associated with poor prognosis and treatment resistance. Therefore, IAP proteins represent relevant targets for therapeutic intervention. Second mitochondrial activator of caspases (Smac) is a mitochondrial protein that is released into the cytosol upon the induction of programmed cell death and promotes apoptosis by neutralizing IAP proteins. On the basis of this property, a variety of small-molecule inhibitors have been developed that mimic the binding domain of the native Smac protein to IAP proteins. Evaluation of these Smac mimetics in preclinical studies revealed that they particularly synergize together with agents that trigger the death receptor pathway of apoptosis. Such combinations might therefore be of special interest for being included in the on going evaluation of Smac mimetics in early clinical trials. © 2014 American Association for Cancer Research.
CITATION STYLE
Fulda, S. (2014). Molecular pathways: Targeting death receptors and Smac mimetics. Clinical Cancer Research, 20(15), 3915–3920. https://doi.org/10.1158/1078-0432.CCR-13-2376
Mendeley helps you to discover research relevant for your work.